Supplementary Figure 7 from SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve &lt;i&gt;ALK-, ROS1-&lt;/i&gt;, or &lt;i&gt;EGFR&lt;/i&gt;-altered Non–small Cell Lung Cancer